One of the fastest growing investment areas in biotech is around enabling technologies and platforms, such as gene and cell therapies, ADCs, RNA technologies and AI/ML applications. And with good reason, as a single platform deal has the potential to fuel a multitude of life-saving treatments.
In this panel, Mike Ward was joined by industry leaders from big pharma and biotech companies to discuss learnings from their technology partnerships and examine what factors help drive successful deals and long-term portfolio value.
Takeaways from this panel include: